Chimerix (NASDAQ:CMRX) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Chimerix (NASDAQ:CMRX) in a research note issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on CMRX. Jefferies Financial Group restated a “hold” rating and set a $8.50 target price (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. HC Wainwright restated a “neutral” rating and set a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Wedbush restated a “neutral” rating and set a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Price Performance

Shares of CMRX opened at $8.54 on Friday. Chimerix has a 12-month low of $0.75 and a 12-month high of $8.55. The firm has a market capitalization of $801.09 million, a price-to-earnings ratio of -9.09 and a beta of -0.17. The stock’s 50-day moving average price is $8.52 and its 200 day moving average price is $5.06.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.31 million. Equities research analysts expect that Chimerix will post -0.99 EPS for the current year.

Hedge Funds Weigh In On Chimerix

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Beryl Capital Management LLC bought a new position in Chimerix in the 1st quarter valued at $33,421,000. Magnetar Financial LLC bought a new position in Chimerix in the 1st quarter valued at $33,337,000. Deerfield Management Company L.P. Series C bought a new position in Chimerix in the 4th quarter valued at $13,124,000. Alliancebernstein L.P. bought a new position in Chimerix in the 1st quarter valued at $31,496,000. Finally, Rosalind Advisors Inc. bought a new position in Chimerix in the 4th quarter valued at $10,614,000. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.